United States
|
|
| Product Center | |
 RPR Liquid Controls 18 mm circle |
|
| Cat. # | Desc. | Qty. | Unit |
| 276909 | RPR Liquid Controls 18 mm circle | EA |
| Product Image (select to enlarge) | |||||||||
 |
| Catalog # | Description | Quantity | Unit |
| 276909 |
RPR Liquid Controls 18 mm circle
controls Reactive(++), Minimal Reactive(+), Nonreactive (-) 1.5 mL each
|
EA |
The Macro-Vue™ RPR (Rapid Plasma Reagin) Card Test Liquid Controls are designed as an unassayed control material to monitor, at three reaction levels, the precision of Macro-Vue RPR 18 mm Circle Card Test.
The Macro-Vue™ RPR (Rapid Plasma Reagin) Card Test Liquid Controls are designed as an unassayed control material to monitor, at three reaction levels, the precision of Macro-Vue RPR 18 mm Circle Card Test.
RPR Test Reagents should be routinely tested for patterns of graded reactivity against controls with established patterns of reactivity. RPR Test Reagents should be routinely tested for patterns of graded reactivity against controls with established patterns of reactivity. Macro-Vue RPR Card Test Liquid Controls contains pooled human serum with 0.1% sodium azide as a preservative.
For in vitro Diagnostic Use. Reagents: Do not use beyond the expiration date. Upon removal from refrigeration allow reagents to warm to room temperature (23–29°C) and gently invert to mix. Avoid microbial contamination of reagents. The serum used for the Controls is derived from human blood tested by an FDA (U.S. Food and Drug Administration) approved method for the presence of the antibody to HIV (human immunodeficiency virus), HBsAg (Hepatitis B surface antigen) and HCsAg (Hepatitis C surface antigen) and found to be nonreactive. WARNING: POTENTIAL BIOHAZARDOUS MATERIAL. Because no test method can offer complete assurance that HIV, hepatitis B virus, hepatitis C virus or other infectious agents are absent, SPECIMENS AND THESE REAGENTS SHOULD BE HANDLED AS THOUGH CAPABLE OF TRANSMITTING AN INFECTIOUS DISEASE. The FDA recommends such material be handled at a Biosafety Level 2. BSL2 is referenced in the Centers for Disease Control and Prevention/National Institutes of Health (CDC/NIH) manual, Biosafety in Microbiological and Biomedical Laboratories. Reagents contain sodium azide, which is very toxic by inhalation, in contact with skin, and if swallowed. Contact with acids liberates very toxic gas. After contact with skin, wash immediately with plenty of water. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. If the established reactivity patterns are not seen, delay routine testing until satisfactory reactivity is obtained by rechecking antigen suspension, test procedures, room temperature and equipment (including use of a rotator with humidifying cover). Non-acceptable results invalidate tests on individual specimens. Diagnostic Test Cards: These are specially prepared cards designed for use with the RPR Card antigen. In handling, take care not to fingermark the card test areas, as this may result in an oily deposit and improper test results. When spreading specimens within the confines of test areas, avoid scratching the card with the Dispenstirs™ device or stirrer. If the specimen does not spread to the outer perimeter of the test area, use another test area of the card. Reading of Card Test Results: Read immediately following rotation in the "wet" state under a high intensity incandescent lamp or strong daylight. Rotation: The recommended speed for mechanical rotation is 100 ± 2 rpm. The rotator should circumscribe a circle approximately two centimeters in diameter in the horizontal plane. A moistened humidifying cover should be used to prevent drying of control sera during rotation. Any sign of microbial contamination warrants discontinuance of use. | ||||||||||||||||||||||||||
Information shown on this page is a short summary extracted from the Package Insert, available as a PDF under the Related Documents section of this page.
